• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Chief Financial Officer Cruickshank Tim

    5/1/25 11:06:06 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care
    Get the next $BEAT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Cruickshank Tim

    (Last) (First) (Middle)
    2118 WALSH AVE
    SUITE 210

    (Street)
    SANTA CLARA CA 95050

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    HeartBeam, Inc. [ BEAT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    04/07/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Common Stock (right to buy) $1.65 04/07/2025 A 150,000 04/07/2025(1) 04/07/2035 Common Stock 150,000 $0 550,000 D
    Explanation of Responses:
    1. Granted 150,000 options on April 7, 2025, which are scheduled to vest over 4 years with 25% vesting on April 7, 2025, and the remainder vesting and exercisable monthly thereafter. These options have been issued from the Company's 2022 Equity Incentive Plan.
    /s/ Tim Cruickshank 05/01/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BEAT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BEAT

    DatePrice TargetRatingAnalyst
    12/20/2021$9.00Speculative Buy
    Benchmark
    More analyst ratings

    $BEAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Heartbeam Inc.

      SC 13D - HeartBeam, Inc. (0001779372) (Subject)

      10/25/23 4:01:55 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by Heartbeam Inc.

      SC 13D - HeartBeam, Inc. (0001779372) (Subject)

      8/28/23 4:26:34 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by Heartbeam Inc.

      SC 13D - HeartBeam, Inc. (0001779372) (Subject)

      6/2/23 2:36:13 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ferrari Richard bought $50,000 worth of shares (29,412 units at $1.70), increasing direct ownership by 20% to 179,136 units (SEC Form 4)

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      2/21/25 8:00:22 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • CFO Cruickshank Tim bought $30,000 worth of shares (17,647 units at $1.70) (SEC Form 4)

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      2/21/25 7:55:14 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $BEAT
    Financials

    Live finance-specific insights

    See more
    • MDB Capital Holdings Provides First Quarter 2025 Update

      Addison, TX, May 21, 2025 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading disruptive technology companies, today provides an update on operations through and subsequent to the quarter ended March 31, 2025. First Quarter 2025 and Subsequent Operational Highlights Closed a public offering of common stock for HeartBeam, Inc (NASDAQ:BEAT) with gross proceeds of approximately $11.5 million. Completed LOIs for 3 new "Big Idea" companies to launch in 2025.Increased our MDBH shareholder base by 4.5% during Q1 2025.Onboarded 111 new MDB Direct accounts during the first quarter, a 26% i

      5/21/25 9:00:00 AM ET
      $BEAT
      $MDBH
      Medical/Dental Instruments
      Health Care
      Finance: Consumer Services
      Finance
    • HeartBeam Announces Two New U.S. Patents, Powering Forward Its Robust Patent Portfolio

      First patent significantly advances intellectual property for HeartBeam's credit card-sized ECG device, bolstering both the defensive and offensive moat around the company's core technology Second patent expands the use of risk-based diagnostic algorithms into HeartBeam's product portfolio around wearable devices HeartBeam now has 20 issued patents worldwide, cementing Company's leadership in cardiac monitoring innovation HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the addition of two new U.S. patents, reinforcing its core intellectual property position and enabling futur

      5/6/25 7:00:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth

      Board expansion reflects Company's commitment to leadership and innovation in remote cardiac monitoring HeartBeam, Inc., (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the appointment of Chief Executive Officer, Robert Eno, to its Board of Directors. As the Company continues to make significant advancements towards commercial readiness, the Board elected to expand from eight to nine members to accommodate this addition. Mr. Eno joined HeartBeam as President in January 2023 and was appointed CEO in October 2024. With over 30 years of experience in the medical technology industry, he has a proven

      5/5/25 7:00:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam to Host First Quarter 2025 Results Conference Call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern Time

      HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2025, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the web

      5/1/25 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam to Host Fourth Quarter Full Year 2024 Results Conference Call on Thursday, March 13, 2025 at 4:30 p.m. Eastern Time

      HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Thursday, March 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2024, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be

      2/27/25 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam Reports Third Quarter 2024 Results

      Continued Clinical and Regulatory Progress on the HeartBeam System Key Appointments to Management Team Completed as Part of Planned Evolution in Preparation for US Commercialization Strengthening Clinical Evidence Base, with Two Additional Studies to be Presented at the American Heart Association Conference in November 2024 Management to Host Webcast and Conference Call Today at 4:30 p.m. ET HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported its financial and operational results for the third quarter ended September 30, 2024. Third Quarter & Subsequent 2024 Operational Highlights

      11/7/24 4:05:00 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Cruickshank Tim

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      5/1/25 11:06:06 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Eno Robert Paul

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      5/1/25 11:05:46 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Technology Officer Persen Kenneth Harry

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      5/1/25 11:03:46 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Benchmark initiated coverage on BioTelemetry with a new price target

      Benchmark initiated coverage of BioTelemetry with a rating of Speculative Buy and set a new price target of $9.00

      12/20/21 7:19:06 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Leadership Updates

    Live Leadership Updates

    See more
    • HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth

      Board expansion reflects Company's commitment to leadership and innovation in remote cardiac monitoring HeartBeam, Inc., (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the appointment of Chief Executive Officer, Robert Eno, to its Board of Directors. As the Company continues to make significant advancements towards commercial readiness, the Board elected to expand from eight to nine members to accommodate this addition. Mr. Eno joined HeartBeam as President in January 2023 and was appointed CEO in October 2024. With over 30 years of experience in the medical technology industry, he has a proven

      5/5/25 7:00:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology

      First cable-free, ambulatory ECG that captures the heart's electrical signals from three distinct directions for high-fidelity data collection and advanced diagnostics Patients can have the credit card-sized device with them at all times, ready to record an ECG whenever they feel symptoms and reduce delays in care Company to initiate Early Access Program to gain important patient and physician feedback on the use of the system in preparation for commercial launch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the US Food and Drug Administration (FDA) has granted 510(k) cl

      12/16/24 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization

      Industry leader brings extensive experience in developing go-to-market strategies for breakthrough products and delivering growth Founder and current CEO Branislav Vajdic named President to focus on advancing the Company's groundbreaking vector-based technology for heart health, including AI applications HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful insights wherever the patient is, announced that Robert Eno has been appointed Chief Executive Officer (CEO), effective Monday, October 21, 2024. The seasoned MedTech executive joined HeartBeam as President in January 2023 and will lead as the Company continues to work

      10/17/24 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Heartbeam Inc.

      DEF 14A - HeartBeam, Inc. (0001779372) (Filer)

      5/28/25 9:12:56 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form PRE 14A filed by Heartbeam Inc.

      PRE 14A - HeartBeam, Inc. (0001779372) (Filer)

      5/16/25 9:10:31 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Heartbeam Inc.

      10-Q - HeartBeam, Inc. (0001779372) (Filer)

      5/13/25 4:04:02 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care